A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice.

ABSTRACT: The safety of systemic fluoropyrimidines (e.g., 5-fluorouracil, capecitabine) is impacted by germline genetic variants in DPYD, which encodes the dihydropyrimidine dehydrogenase (DPD) enzyme that functions as the rate-limiting step in the catabolism of this drug class. Genetic testing to identify those with DPD deficiency can help mitigate the risk of severe and life-threatening fluoropyrimidine-induced toxicities. Globally, the integration of DPYD genetic testing into patient care has varied greatly, ranging from being required as the standard of care in some countries to limited clinical use in others. Thus, implementation strategies have evolved differently across health systems and countries. The primary objective of this tutorial is to provide practical considerations and best practic

SUBMITTER: Ho TT 

PROVIDER: S-EPMC11993294 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature